Markets

Insider Trading

Hedge Funds

Retirement

Opinion

JPMorgan Chase & Co. (JPM): Among the Best Fortune 500 Stocks to Buy Now

We recently compiled a list of the 10 Best Fortune 500 Stocks To Buy Now. In this article, we are going to take a look at where JPMorgan Chase & Co. (NYSE:JPM) stands against the other Fortune 500 stocks.

Should Investors Be Overly Cautious?

The aggregate revenue of the Fortune 500 companies in 2023 reached a record $41 trillion, up 0.1% year-over-year. Profits also rose 2% after declining earlier in 2022. The US took the lead from Greater China with the most companies on the Fortune 500 list for the first time since 2018. It has 139 companies as of August this year, an increase of 3 from 2023, while Greater China has 133 companies, down 9 from last year.

The financial sector, including banks and insurance companies, led all industries with the most Fortune 500 companies. Collectively tech giants brought in $282 billion in net income, up from $233 billion the previous year. Currently, 13 companies are making their Fortune 500 debut, reflecting the world’s fascination with AI and weight-loss drugs.

While the S&P 500 has recovered most of its losses, the rebound is being led by sectors like real estate, utilities, and consumer staples rather than major tech companies. Investors are shifting focus due to concerns over economic growth and expectations of Fed rate cuts.

Still, it seems like investors think that while investment portfolios should be diversified given the current economic conditions, this sentiment does not imply divesting from tech stocks, which of course contribute greatly to the aggregate Fortune 500 revenue. Jason Draho, UBS Global Wealth Management head of Americas Asset Allocation, emphasized this sentiment and we covered this earlier in our article about the 10 Best Tech Stocks To Buy Right Now Under $10:

“…investors should view potential dips in tech stocks as good long-term buying opportunities, as 10% corrections are historically good entry points in tech… He thinks that this market volatility is acyclical. The recent sell-off in the tech sector was not primarily due to economic concerns but rather to sector-specific issues. Despite this, tech giants will continue to benefit from the AI CapEx investment story. While there may be short-term challenges, the long-term outlook for these companies remains positive… Draho also cautioned against over-concentrating portfolios in the sector. He suggested diversifying exposure by investing in sector leaders as well as companies likely to benefit from tech disruption as a way to manage potential downside risks in tech stocks.”

Just last week, Dan Greenhaus, Solus Alternative Asset Management’s chief strategist discussed markets, and the rebound’s staying power, all while suggesting that predicting the Fed’s next move had become more difficult.

He discussed the ongoing recession concerns, particularly after negative comments from financial representatives. Despite these worries, he believes the US consumer is performing well, the economy is stable, and corporate profits are exceeding expectations. This context suggests that the recent sell-off in certain AI stocks was followed by a justified rebound, as issues appear limited to recent trends.

The S&P 500 is currently facing resistance around the 5,600 level, a key point of concern for investors. Dan Greenhaus noted that the recent inversion of the yield curve raised anxiety but the 2-10-year curve is slightly positive. Despite these worries, credit spreads for investment-grade bonds remain stable, and overall cross-asset indicators suggest a stable market environment.

Recently, discussions around potential interest rate changes have gained momentum, particularly following insights from Goldman Sachs CEO David Solomon. He indicated a likely 25 basis point cut by the Federal Reserve, although he also acknowledged the possibility of a 50 basis point reduction. Greenhaus believes the Fed will opt for a 25 basis point cut, marking the start of a series of reductions. This perspective is supported by the normalization of inflation and a slowing economy.

According to Greenhaus, the cyclical components of the stock market appear to be performing well, indicating that the overall economic fundamentals remain robust, and there is no concrete case for any specific rate cut scenario. As Fortune 500 companies continue to generate record revenues and profits as well, investor sentiments should not be shifting drastically. With that being said, we’re here with a list of 10 best Fortune 500 stocks to buy now.

Methodology

We first looked at the list of Fortune 500 companies, as of 2024. We then selected 10 stocks from these Fortune 500 companies that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q2 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

A group of business people discussing plans around a boardroom table adorned with a financial services company logo.

JPMorgan Chase & Co. (NYSE:JPM)

Market Capitalization as of September 14: $582.50 billion

Number of Hedge Fund Holders: 111

JPMorgan Chase & Co. (NYSE:JPM) is a multinational finance company and one of the world’s largest banks by market capitalization, offering a wide range of financial services to individuals, businesses, and institutions that include commercial banking, investment banking, asset management, wealth management, and consumer banking.

As of March 31, it had $4.1 trillion in assets and $3.6 trillion in assets under management, solidifying its status as the largest bank in the US. In just Q1 this year, the company generated $655 million in total credit and capital for consumers, small businesses, government entities, and nonprofit organizations.

JPMorgan Chase & Co. (NYSE:JPM) is automating internal tasks and enhancing customer experiences. In August, it launched a GenAI assistant to help ~60,000 employees complete tedious tasks more efficiently. For customers, it introduced in-store pay-by-face biometric payment solutions for merchants in the US. Earlier in May, the company also launched a new data-managed service for institutional investors to streamline their operating models and access consistent data.

As of June 30, the company was held by 111 hedge funds, of which the largest stake is valued at $2,576,879,756 by Fisher Asset Management.

The company’s future is looking at sustained success due to its cost advantages and strategic investments in organic growth. With robust financial performance and its size and scale, JPM is set to benefit.

Carillon Eagle Growth & Income Fund stated the following regarding JPMorgan Chase & Co. (NYSE:JPM) in its first quarter 2024 investor letter:

JPMorgan Chase & Co. (NYSE:JPM) contributed positively to performance following solid financial results and positive guidance for the remainder of 2024. Moreover, growing chatter around rising capital markets activity likely contributed to the stock’s strong performance relative to other banks. Recall that JPMorgan has a robust capital markets franchise.”

Overall JPM ranks 7th on our list of the best Fortune 500 stocks to buy. While we acknowledge the potential of JPM as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than JPM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…